MedTrace Logo

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

NCT06005740 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-03-04

No results posted yet for this study

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.

For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).

Conditions

Interventions

DRUG

TORL-4-500

antibody drug conjugate

Sponsors & Collaborators

  • Translational Research in Oncology

    collaborator OTHER

  • TORL Biotherapeutics, LLC

    lead INDUSTRY

Principal Investigators

  • Caroline Labib, PharmD · TORL Biotherapeutics, LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-04
Primary Completion
2025-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06005740 on ClinicalTrials.gov